Pentoxifylline - Mayfield Pharmaceuticals
Alternative Names: MAY-66Latest Information Update: 28 Aug 2023
At a glance
- Originator TGV Health
- Developer Mayfield Pharmaceuticals
- Class Anti-inflammatories; Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
- Mechanism of Action Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial vaginosis; Peyronie's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Bacterial-vaginosis(Prevention) in USA
- 28 Jun 2023 No recent reports of development identified for research development in Peyronie's-disease in USA (IV, Injection)
- 31 May 2021 Mayfield Pharmaceuticals terminates a licensing agreement with TGV Health before May 2021